Connect. Collaborate.
Catalyze. Join our team
at DCAT 2024
March 18th - 21st -2024
LOTTE New York Palace Hotel455 Madison Avenue, New York, NY 10022 (Madison at 50th Street)
Our Team at DCAT 2024
-
Deepak Sapra
CEO, Pharmaceutical Services and Active Ingredients
-
Gunjan Singh
Vice President and Head – North America, Canada and Europe
-
R Lalitha Kumari
Global Head of Product Management & Head of Sales - US & Canada
-
Kalpesh Kumar Modi
Vice President and Region Head – Europe
-
Juli Asmonga
Associate Vice President – US
-
B Vivek
Executive VP and Global Head – Supply, Demand Planning and Delivery
-
Dr. Rajeev Rehani Budhdev
Executive Vice President – API R&D
-
E Sreedhar
Executive Vice President – API Regulatory Affairs
About DCAT 2024
Scheduled from March 18-21 in New York City, DCAT Week 2024 is positioned as the premier event for the Global Bio/Pharmaceutical Manufacturing Value Chain. Hosted by the not-for-profit Drug, Chemical & Associated Technologies Association (DCAT), the conference brings together a diverse range of industry participants, including innovator and generic drug manufacturers, suppliers, and technology providers.
Host: Drug, Chemical & Associated Technologies Association (DCAT)
DCAT, a not-for-profit organization with a membership model that integrates various industry stakeholders, plays the role of a facilitator in the pharmaceutical and chemical sectors. Its global perspective and member-supported structure position it as a neutral platform for collaboration and knowledge exchange.
Event Objectives
The primary objective of DCAT Week is to serve as a forum for professionals within the Bio/Pharmaceutical Manufacturing Value Chain. Attendees can expect a focus on knowledge dissemination, networking opportunities, and discussions around industry trends and challenges
Inclusive Participation
The event is open to a wide spectrum of participants, encouraging inclusivity among innovators, generic drug manufacturers, suppliers of ingredients, development and manufacturing services, as well as technology providers. This diversity in participation fosters an environment where different perspectives and expertise can be shared for the collective benefit of the industry
Knowledge Exchange
DCAT Week aims to provide a platform for the exchange of knowledge and best practices. Participants can anticipate discussions on the latest innovations and technologies shaping the bio/pharmaceutical sector. The event aims to facilitate a neutral space for industry professionals to learn from one another and stay informed about advancements in drug development and manufacturing.
Member Involvement
DCAT Week relies on the active engagement of its members to contribute to the event's success. The association's member-supported model ensures that the event remains a reflection of the industry's collective intelligence. Member involvement extends beyond the event dates, contributing to a dynamic and ongoing platform for collaborative endeavors.
About Dr.Reddy's API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 180+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
ENQUIRE NOWSustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
Our Achievements
15/02/2023
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row
15/02/2023
S&P Global’s Sustainability Yearbook for the 3rd year
04/11/2022
Dr. Reddy’s API received the excellence in API – Technical Documentation award at Aché Laboratórios Parcerias para a Excelência (Partnerships – Excellence) event!
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
11/11/2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
19/10/2020
Dr. Reddy's recognized at the CPhI Pharma Awards 2020 as the winner in the category of ‘Excellence in Pharma: Sustainability’
03/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2020
05/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2019
Our API Manufacturing Units
Disclaimer
No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.